Medicus Pharma (MDCX) CFO awarded 75,000 stock options vesting over one year

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported an equity award for its President and CFO, Carolyn F. Bonner. On December 16, 2025, she received a stock option grant covering 75,000 common shares at an exercise price of $1.8 per share. These options are scheduled to vest quarterly in four equal installments over one year, meaning portions of the grant become exercisable every quarter during that period.

After this grant, she held 75,000 derivative securities directly, all tied to the company’s common shares. This type of award is a common form of equity-based compensation that links an executive’s potential future gains to the company’s share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonner Carolyn F.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W.CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.8	12/16/2025		A		75,000		(1)	12/16/2030	Common Shares	75,000	$0	75,000	D

Explanation of Responses:

1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Carolyn F. Bonner	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medicus Pharma (MDCX) report for its CFO?

Medicus Pharma reported that its President and CFO, Carolyn F. Bonner, received a stock option grant on December 16, 2025 for 75,000 options on the company’s common shares.

What is the exercise price of the stock options granted to the Medicus Pharma (MDCX) CFO?

The stock options granted to the President and CFO of Medicus Pharma have an exercise price of $1.8 per share.

How do the Medicus Pharma (MDCX) CFO’s new stock options vest?

The option granted on December 16, 2025 is scheduled to vest quarterly in four equal installments over one year, so one-quarter of the grant vests each quarter.

How many Medicus Pharma (MDCX) derivative securities does the CFO own after this transaction?

Following the reported transaction, the President and CFO beneficially owned 75,000 derivative securities, all in the form of stock options tied to Medicus Pharma common shares.

Is the Medicus Pharma (MDCX) CFO’s stock option ownership direct or indirect?

The Form 4 indicates that the 75,000 stock options are held with direct ownership by the reporting person.

When do the Medicus Pharma (MDCX) CFO’s stock options expire?

The reported stock options granted on December 16, 2025 have an expiration date of December 16, 2030.